International Journal of Molecular and Cellular Medicine, published by the CELLULAR & MOLECULAR BIOLOGY RESEARCH CENTER in Iran, is a leading platform dedicated to advancing research in various domains of molecular and cellular sciences. With an ISSN of 2251-9637 and E-ISSN 2251-9645, this journal features a rigorous peer-review process that ensures the publication of high-quality, impactful research. Spanning from 2016 to 2024, it is categorized in the third quartile (Q3) in Biochemistry, Cell Biology, Genetics, and Molecular Biology, and second quartile (Q2) in Biotechnology, underlining its significance in the scientific community. Although currently non-open access, it maintains credible visibility through Scopus rankings, reflecting its importance in fields such as Biochemistry, Molecular Medicine, and Genetics, where it holds respectable ranks and percentiles. This journal aims to foster collaboration and knowledge dissemination among researchers, professionals, and students in the pursuit of enhancing understanding and innovation in molecular and cellular medicine.

Turk Onkoloji Dergisi - Turkish Journal of Oncology, published by KARE PUBL, serves as a vital platform in the field of oncology, specifically catering to the Turkish-speaking research community and contributing to global discourse. With an ISSN of 1300-7467, this journal, which has been in circulation since 2007 and continues until 2024, recognizes the importance of advancing medical knowledge in cancer research through rigorous peer-reviewed articles. Although currently positioned in the Q4 category of oncology journals with a Scopus rank of #344 out of 404, the journal is dedicated to fostering significant research insights and innovative perspectives on cancer treatment and prevention. While it does not currently offer open access, its content is essential for professionals, researchers, and students aiming to enhance their understanding of oncology developments in Turkey and beyond. The Turkish Journal of Oncology not only aspires to improve the quality of cancer care but also strives to enhance collaboration among researchers, thereby influencing future oncology practices.

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

ANNALS OF ONCOLOGY, published by Elsevier, stands as a premier journal in the field of oncology, hematology, and general medicine, with a notable impact factor that underscores its significance in advancing cancer research and clinical practice. Established in 1990, this journal has become a highly respected source of information, consistently ranked in the Q1 category in its respective fields, showcasing its influence and credibility (Rank #4/404 in Oncology and Rank #2/137 in Hematology as per Scopus rankings). With a focus on innovative therapies, clinical trials, and emerging research, ANNALS OF ONCOLOGY serves as an essential resource for researchers, clinicians, and students dedicated to unraveling the complexities of cancer treatment and care. Although offering restricted access options, its impactful studies and discoveries continue to shape the future of oncology.

Biomolecules & Therapeutics is a prominent journal published by the Korean Society of Applied Pharmacology, dedicated to advancing knowledge in the fields of Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With an ISSN of 1976-9148 and an E-ISSN of 2005-4483, this journal serves as a vital platform for researchers and professionals to disseminate their findings from 2008 through 2024. Ranking in the Q2 category across multiple relevant fields, including Pharmacology and Drug Discovery, and consistently placing in the 60th to 70th percentiles in Scopus rankings, Biomolecules & Therapeutics exemplifies a commitment to high-quality research and scientific integrity. Although it operates on a traditional access model, readers can be assured of the journal's rigorous peer-review process, ensuring that published articles contribute meaningfully to ongoing discourse in pharmacological and biochemical research. Located in Seoul, South Korea, the journal stands at the forefront of innovation in healthcare, making it an essential resource for academics, students, and industry professionals alike.

BioImpacts, an esteemed journal published by Tabriz University of Medical Sciences & Health Services, is a prominent platform dedicated to advancing the fields of Biochemistry, Genetics, Molecular Biology, Medicine, and Pharmaceutical Science. Established in 2011, this Open Access journal ensures that vital research findings are freely accessible to the global academic community. With an impressive presence in the Scopus database, BioImpacts currently holds a Q2 quartile ranking in its respective categories, reflecting its contribution to scientific discourse and its importance as a critical resource for researchers and practitioners alike. The journal's dynamic scope encompasses a wide range of topics, highlighting innovative research that addresses contemporary challenges in health and disease. Operating out of Tabriz, Iran, BioImpacts is committed to fostering interdisciplinary collaboration and knowledge dissemination through their dedicated publication efforts, which span from 2011 to 2024. Researchers, professionals, and students are encouraged to explore the rich content and cutting-edge studies presented in this journal, making it an indispensable resource in the scientific community.

Cancer Reports, published by WILEY, is an esteemed open-access journal dedicated to the field of oncology and cancer research. With a focus on disseminating impactful research findings since its transition to fully open access in 2021, Cancer Reports aims to facilitate knowledge sharing among researchers, clinicians, and healthcare professionals globally. The journal is positioned within the Q3 quartile for both Cancer Research and Oncology categories as of 2023, reflecting its commitment to quality and relevance in a competitive publishing landscape. With an ISSN of N/A and an E-ISSN of 2573-8348, the journal showcases studies across diverse aspects of cancer biology, treatment modalities, and patient care strategies. Located in the United Kingdom at 111 River St, Hoboken 07030-5774, NJ, Cancer Reports strives to contribute to the advancement of cancer research and improve health outcomes for patients worldwide, making it a pivotal platform for scholars and practitioners in the oncology community.

Recent Patents on Anti-Cancer Drug Discovery, published by Bentham Science Publishers Ltd, is an esteemed peer-reviewed journal specializing in the innovative intersection of pharmaceutical science and oncology. With an ISSN of 1574-8928 and an E-ISSN of 2212-3970, this journal aims to provide a comprehensive platform for the dissemination of recent developments in anti-cancer drug discovery, addressing critical issues and breakthroughs that influence cancer research and treatment. The journal spans from 2006 to 2024 and is indexed in several prestigious databases, showcasing its relevance with a Q3 ranking in key categories such as Cancer Research and Drug Discovery as of 2023. Its status of being open access reflects a commitment to making valuable scientific findings widely available, promoting collaboration and advancement in the field. With a dedicated focus on advancing knowledge in cancer therapeutics, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to contribute to the fight against cancer.

Cancer Treatment Reviews, published by Elsevier Science Ltd, is a leading international journal dedicated to the exploration and advancement of therapeutic strategies in oncology. With an impressive impact factor that reflects its status in the field, this journal is classified within Q1 quartile rankings in Medicine (Miscellaneous), Oncology, and Radiology, Nuclear Medicine and Imaging, as of 2023. The journal has a rich lineage, having been established in 1974 and consistently evolving to encompass the latest breakthroughs and methodologies in cancer treatment. A vital resource for researchers, clinicians, and students alike, it aims to promote understanding and application of effective interventions, thereby contributing to improvements in patient outcomes. By prioritizing high-quality reviews, Cancer Treatment Reviews plays an essential role in bridging the gap between current research and clinical practice, making it an indispensable asset in the continuous fight against cancer.

Cancer Nanotechnology is a cutting-edge peer-reviewed journal dedicated to advancing the field of cancer research through innovative nanotechnology applications. Published by SPRINGER WIEN, this open-access journal, established in 2010, provides a vital platform for the dissemination of high-quality research with a focus on the intersection of nanotechnology, oncology, and biomedical engineering. With a commitment to promoting accessibility and fostering collaboration, Cancer Nanotechnology has gained impressive rankings within specialized categories, including Q2 in Biomedical Engineering and Pharmaceutical Science. The journal's rigorous selection process ensures that only the most impactful studies reach its audience, making it a must-read for researchers, professionals, and students eager to explore the latest advancements and methodologies in cancer treatment. With its scope encompassing critical topics that bridge multiple disciplines—including physical chemistry and toxicology—Cancer Nanotechnology positions itself as an influential resource for shaping the future of cancer therapies.